As pandemic restrictions begin to loosen in many communities across the country, patients with chronic lymphocytic leukemia (CLL) face greater uncertainty in this “new normal” due to their increased risk for contracting COVID-19 and a lower response rate to the vaccine.
On this episode, three clinicians discuss their experiences with difficult conversations on the relative risks and benefits around treatment decisions, engaging the entire cancer team in shared decision-making with patients, accessing emerging evidence and data in this rapidly evolving environment, and the potential impact of variant exposure on this unique patient population.
John N. Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, NY
Mark J. Fesler, MD
Director, Bone Marrow Transplant Program, Associate Professor of Internal Medicine
Division of Hematology and Oncology
Saint Louis University
St. Louis, MO
Susannah P. Friemel, MD
Iowa Cancer Specialists, PC
This podcast is produced as part of the “Returning to Practice in the Post-COVID-19 Era: Hematology Disease Education” program. Funding & support provided by AbbVie. Learn more here.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.